SavedAdd your journal

Journals / Turkish Journal of Hematology / 2015 / Cilt: 32 - Sayı: 2

Konvansiyonel Tedavilere ve Splenektomiye Refrakter Primer Myelofibrozisli Olguda Ruxolitinib Deneyimi

Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report

MELTEM AYLI
Muhit ÖZCAN
GÜLDANE CENGİZ SEVAL
Pages
180–183
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This is the first case report that shows the effects of ruxolitinib in a splenectomized patient.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A 67-year-old male patient who was diagnosed with primary myelofibrosis 4 years ago did not respond to conventional therapies.
📊
Key Findings & Data:The splenomegaly progressively increased, which caused spleen infarctions and led to the decision to perform a splenectomy procedure.
💡
Conclusion & Impact:This is the first case report that shows the effects of ruxolitinib in a splenectomized patient.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

A 67-year-old male patient who was diagnosed with primary myelofibrosis 4 years ago did not respond to conventional therapies. The splenomegaly progressively increased, which caused spleen infarctions and led to the decision to perform a splenectomy procedure. After splenectomy, the patient started treatment with ruxolitinib. In the first month of ruxolitinib treatment, the patient became transfusion-free and all constitutional symptoms disappeared. However, in the sixth month of ruxolitinib treatment, the disease transformed to acute myeloblastic leukemia, and the patient died 1 month later. This is the first case report that shows the effects of ruxolitinib in a splenectomized patient.

Özet

Dört yıl önce primer myelofibrozis tanısı konulan 67 yaşındaki erkek hastaya uygulanan konvansiyonel tedavi yöntemleri ile sonuç alınamadı. Dalak boyutları ileri derecede arttı, hastanın tekrar ayda 4-6 ünite transfüzyon gereksinimi olmaya başladı. Bu dönemde dev boyutlara ulaşan dalakta infarktüs gelişti ve hastaya splenektomi yaptırıldı. Splenektomi sonrası hastaya ruxolitinib başlandı. Ruxolitinib tedavisinin 1. ayından itibaren hasta transfüzyon bağımsız hale geldi, tüm konstitüsyonel semptomlar ortadan kalktı. Ancak ruxolitinib tedavisinin 6. ayında hasta akut myeloblastik lösemiye (AML) transfore oldu. Ve AML tedavisinin 1. ayında hasta kaybedildi. Bu olgu splenektomi yapılmış bir hastada ruxolitinib etkisini gösteren ilk olgudur.

🔖

Cite This Article

AYLI, M., ÖZCAN, M., SEVAL, G. C. (2015). Konvansiyonel Tedavilere ve Splenektomiye Refrakter Primer Myelofibrozisli Olguda Ruxolitinib Deneyimi. Turkish Journal of Hematology, Cilt: 32 - Sayı: 2, 180–183. https://ajindex.com/articles/412513

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000;342:1255-1265
  2. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007;7:673-683
  3. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790
  4. Vaddi K, Sarlis NJ, Gupta V. Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis. Expert Opin Pharmacother 2012;13:2397-2407
  5. Abdel-Wahab OI, Levine RL. Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annu Rev Med 2009;60:233-245
  6. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895-2901
  7. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kröger N, Mesa R, McMullin MF, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi A; European LeukemiaNet. Philadelphia- negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011;29:761-770
  8. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vadi K, Viitanen SE, Koumenis IL, Sun W, Sandor W, Kantarjian HM. A double-blind, placebo- controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799-807
  9. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787-798
  10. Tefferi A. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013;88:437-445
  11. Randhawa J, Ostojic A, Vrhovac R, Atallah E, Verstovsek S. Splenomegaly in myelofibrosis-new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors. J Hematol Oncol 2012;5:43.